suven-pharmaceuticals-ltd

Suven Pharmaceuticals Ltd Financials
Company Logo

Suven Pharmaceuticals Ltd Financial Statement

Suven Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue249.49
Operating Expense135.05
Net Profit76.33
Net Profit Margin30.59
Earning Per Share3.00
EBIDTA118.00
Effective Tax Rate24.39

Suven Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual1,024.99
Operating Expenses Annual615.09
Operating Profit Annual464.99
Interest Annual7.43
Depreciation48.29
Net Profit Annual304.82
Tax Annual103.96

Suven Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning43.02
Cash Flow from Operations370.65
Cash Flow from Investing-381.58
Cash Flow from Financing-13.78
Cash Flow at the End18.31

Suven Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)41.10
PBIT Margin (%)36.34
PBT Margin (%)31.45
Net PROFIT Margin (%)29.74
Return On Networth / Equity (%)14.31
Return On Networth /Employed (%)18.82
Return On Assets (%)15.46
Total Debt / Equity (X)0.04
Asset Turnover Ratio (%)0.52

Suven Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual523.65
Total Current Assets Annual1,209.55
Non Current Assets Annual1,031.16
Total Shareholders Funds Annual2,055.90
Total Assets Annual2,240.72

Suven Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

3.23

Reported

3.23

Surprise

0.00%

Jun 2024

EPS beaten by 0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Dec 11, 2024, Suven Pharmaceuticals Ltd has a market capitalization of 17,223.86 Cr. Value Research classifies it as a Large-Cap company.
Yes, Suven Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.03.
In FY 2023 , Suven Pharmaceuticals Ltd recorded a total revenue of approximately 1,024.99 Cr marking a significant milestone in the company's financial performance.
Suven Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.0% and -0.1% annually, respectively..
Suven Pharmaceuticals Ltd's current PE ratio is 56.51.
Suven Pharmaceuticals Ltd's ROCE averaged 32.4% from the FY ending March 2022 to 2024, with a median of 32.5%. It peaked at 45.0% in March 2022, reflecting strong capital efficiency over the period..
Suven Pharmaceuticals Ltd's latest EBIT is Rs. 416.20 Cr, surpassing the average EBIT of Rs. 579.01 Cr over the 5 years..
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions